Erratum to: Monoclonal Antibody Administration

Intravesical administration of radiolabeled antitumor monoclonal antibody in bladder carcinoma.

Tumor associated AUA1 monoclonal antibody and 11.4.1. nonspecific monoclonal antibody, which does not react with human tissues, were radiolabeled with 111In and administered intravesically to 23 patients undergoing cystoscopy for bladder carcinoma. The antibody solution remained in the bladder for 1 h and then was washed out prior to cystoscopy. Tumor and nontumor samples were obtained during c...

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Monoclonal Antibody to a Triggering

The in vitro activation of splenocytes or PBL with rIL-2 generates a population of cytotoxic effector cells with broad antitumor reactivity (1-4) . These lymphokineactivated killer (LAK)' cells have been suggested to be useful for the adoptive immunotherapy of metastatic tumors in animal models and in man (5-7) . LAK cells have the ability to bind and lyse virtually any tumor cell, but do not l...

Preparation of Monoclonal Antibody to Fusion Glycoprotein of Newcastle Disease Virus Isolated from Iran

Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling

Background: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody-dependent phagocytosis by macrophages. Apoptosis induction is another mechanism of this antibody...